AIRNA Bio is developing oligonucleotide-based therapeutics that mediate RNA editing for patients with rare and common diseases. AIRNA uses a unique oligonucleotide drug construct to bind to a specific RNA sequence and then attract endogenous ADAR enzymes to the RNA. ADAR enzymes can mediate the chemical transformation of a specific adenosine (A) to inosine (I), which is read as guanosine (G) when translating RNA to protein. This A-to-I edit can fix pathogenic point mutations, induce therapeutically-effective gain-of-function or loss-of-function mutations, or change protein conformation.

<p>AIRNA Bio is developing oligonucleotide-based therapeutics that mediate RNA editing for patients with rare and common diseases. AIRNA uses a unique oligonucleotide drug construct to bind to a specific RNA sequence and then attract endogenous ADAR enzymes to the RNA. ADAR enzymes can mediate the chemical transformation of a specific adenosine (A) to inosine (I), which is read as guanosine (G) when translating RNA to protein. This A-to-I edit can fix pathogenic point mutations, induce therapeutically-effective gain-of-function or loss-of-function mutations, or change protein conformation.</p>


AIRNA Bio

Founded: 2023
Location: Cambridge, MA
Employee range: 1-50
Funding: 10 - 100M

Short description:

Drug notes:

Long description:

Jobs: